ANI Pharmaceuticals, Inc. (ANIP)

ANI Pharmaceuticals Income Statement

Financials in millions USD. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Sep 30, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Revenue	826.88	614.38	486.82	316.39	216.14	208.48
Revenue Growth (YoY)	48.86%	26.20%	53.87%	46.38%	3.67%	0.93%
Cost of Revenue	324.55	250.21	181.51	138.79	100.61	87.16
Gross Profit	502.34	364.17	305.3	177.6	115.53	121.32
Selling, General & Admin	303.87	237.24	161.7	124.04	84.29	64.99
Research & Development	56.05	44.58	34.29	22.32	11.37	16
Other Operating Expenses	-2.66	-	-	-	0.78	11.26
Operating Expenses	448.67	349.55	255.77	203.33	143.7	136.89
Operating Income	53.66	14.62	49.53	-25.73	-28.17	-15.57
Interest Expense	-32.91	-33.14	-35.05	-28.42	-11.95	-9.48
Interest & Investment Income	11.25	15.53	8.11	0.37	0.02	0.03
Other Non Operating Income (Expenses)	-4.03	-4.03	-0.16	0.67	-4.71	-0.49
EBT Excluding Unusual Items	29.05	-7.02	22.43	-53.12	-44.8	-25.52
Merger & Restructuring Charges	2.42	-12.4	-1.13	-5.68	-	-
Gain (Loss) on Sale of Investments	0.56	6.31	-	-	-	-
Gain (Loss) on Sale of Assets	-0.3	5.35	-	-	1.82	-
Asset Writedown	-8.37	-7.6	-	-0.11	-2.37	-0.45
Legal Settlements	-	-	-	-	-8.75	-
Other Unusual Items	27.18	-6.85	-1.43	-3.76	-1.96	-
Pretax Income	50.55	-22.21	19.87	-62.67	-56.06	-25.96
Income Tax Expense	9.98	-3.69	1.09	-14.77	-13.46	-3.41
Net Income	40.57	-18.52	18.78	-47.9	-42.6	-22.55
Preferred Dividends & Other Adjustments	6.42	1.63	3.3	1.63	0.19	-
Net Income to Common	34.15	-20.15	15.48	-49.52	-42.79	-22.55
Shares Outstanding (Basic)	20	19	18	16	13	12
Shares Outstanding (Diluted)	21	19	18	16	13	12
Shares Change (YoY)	6.95%	6.18%	11.89%	29.09%	5.28%	-0.63%
EPS (Basic)	1.73	-1.04	0.86	-3.05	-3.40	-1.88
EPS (Diluted)	1.67	-1.04	0.85	-3.05	-3.40	-1.88
Free Cash Flow	155.73	47.78	110.09	-40.08	0.77	9.13
Free Cash Flow Per Share	7.58	2.47	6.05	-2.46	0.06	0.76
Gross Margin	60.75%	59.27%	62.71%	56.13%	53.45%	58.19%
Operating Margin	6.49%	2.38%	10.17%	-8.13%	-13.03%	-7.47%
Profit Margin	4.13%	-3.28%	3.18%	-15.65%	-19.80%	-10.82%
Free Cash Flow Margin	18.83%	7.78%	22.61%	-12.67%	0.35%	4.38%
EBITDA	145.07	82.35	109.32	33.92	19.08	29.07
EBITDA Margin	17.54%	13.40%	22.46%	10.72%	8.83%	13.94%
D&A For EBITDA	91.4	67.73	59.79	59.65	47.25	44.64
EBIT	53.66	14.62	49.53	-25.73	-28.17	-15.57
EBIT Margin	6.49%	2.38%	10.17%	-8.13%	-13.03%	-7.47%
Effective Tax Rate	19.74%	-	5.50%	-	-	-

Updated Nov 7, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q